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Neurotrophic keratitis (NK) is a rare degenerative disease of the cornea caused by an impairment of corneal sensory innervation,
characterized by decreased or absent corneal sensitivity resulting in epithelial keratopathy, ulceration, and perforation. The
aetiopathogenesis of corneal sensory innervation impairment in children recognizes the same range of causes as adults, although
they are much less frequent in the pediatric population. Some extremely rare congenital diseases could be considered in the
aetiopathogenesis of NK in children. Congenital corneal anesthesia is an extremely rare condition that carries considerable
diagnostic and therapeutic problems. Typically the onset is up to 3 years of age and the cornea may be affected in isolation or
the sensory deficit may exist as a component of a congenital syndrome, or it may be associated with systemic somatic anomalies.
Accurate diagnosis and recognition of risk factors is important for lessening long-term sequelae of this condition. Treatment should
include frequent topical lubrication and bandage corneal or scleral contact lenses. Surgery may be needed in refractory cases. The
purpose of this review is to summarize and update data available on congenital causes and treatment of corneal hypo/anesthesia
and, in turn, on congenital NK.
1. Introduction
The cornea is the tissue with the richest innervation in the
human body. Marfurt et al. [1] showed that around 70 nerve
bundles enter the cornea at the corneoscleral limbus and
then give rise through repetitive branching to a moderately
dense midstromal plexus and a dense subepithelial plexus.
It is well known that the trigeminal nerve is responsible for
providing sensitivity to the cornea but also for providing a
trophic support through the release of neurotrophic factors
that play a fundamental role in maintaining its anatomical
integrity, transparency, and function.
The ophthalmic branch of the trigeminal nerve has 2
reflex arcs: a motor arc that regulates eyelid movements (i.e.,
blinking) and an autonomic arc that regulates the secretion
of goblet cells and lacrimal and meibomian glands. The
integration of these two reflex arcs is responsible for the
production, maintenance, and stability of the preocular tear
film, which is also responsible for providing a trophic support
to the cornea. Therefore, the impairment of corneal sensory
innervation is overall devastating as it triggers a detrimental
loop in which a reduction in trophic support to the tissue
is accompanied by an aberrant reduction in the lacrimation
reflex and in blinking, with a consequent damage to epithelial
cells, which are also burdened by a parallel deficiency in
spontaneous epithelial repair [2–5].
Patients suffering decrease or absence of corneal sensitiv-
ity develop a clinical condition called neurotrophic keratitis
(NK), also known as neurotrophic keratopathy or neuropara-
lytic keratitis: regardless of the underlying cause, NK is a rare
degenerative disease of the cornea caused by an impairment
of corneal sensory innervation, characterized by decreased
or absent corneal sensitivity (hypo/anaesthesia), resulting
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in spontaneous epithelial breakdown and reduced corneal
healing [6].
NK can be caused by systemic, ocular, congenital, or
iatrogenic diseases that lead to a damage to the fifth cranial
nerve.
2. Aetiopathogenesis
Although a wide range of ocular and systemic diseases may
cause neurotrophic keratitis, one common insult is always
present: a lesion of the fifth (trigeminal) cranial nerve or its
ophthalmic branch [6].
The most common causes of neurotrophic keratitis are
viral infections (herpes simplex and herpes zoster kerato-
conjunctivitis) [7, 8], followed by surgical interventions to
the trigeminal nerve or for acoustic neuroma [9]. In fact,
neurosurgical procedures can cause an insult and consequent
damage to the trigeminal nucleus, root, or ganglion, or also
directly to the ophthalmic branch of the nerve [10, 11]. Toxi-
city from chronic use of topical ocular medications may also
cause nerve damage and result in corneal hypo/anaesthesia
[12, 13]. Neurotrophic keratitis has also been associated
with systemic diseases such as diabetes mellitus [14, 15]. A
complete list of all known causes of NK is provided in Table 1.
Generally speaking, the aetiopathogenesis of corneal sen-
sory innervation impairment in children recognizes the same
range of causes as adults, although they aremuch less frequent
in the pediatric population. In fact, diseases such as uncon-
trolled diabetes and advanced multiple sclerosis and leprosy
are very unrealistic in children, and even herpes simplex
infection, which may occur in children, needs a long history
of recurrences before inducing damage to the corneal nerves.
In addition, it must be considered that corneal and refractive
surgery, as well as abuse of local anesthetics [23, 24], chronic
topical glaucoma therapy [25, 26], and chronic contact lens
wear [27], which are amongst the most common iatrogenic
causes of NK in adults, play a very limited role in childhood.
On the other hand, some extremely rare congenital dis-
eases could be considered in the aetiopathogenesis of NK in
children. Among them, the rare congenital corneal anesthesia
could be a cause of corneal ulceration and scarring in
children. Typical onset is up to 3 years of age,more commonly
between the age of 8 and 12 months. It may occur as an
isolated disease or associated with systemic diseases such
as familial dysautonomia (Riley-Day syndrome), Goldenhar
syndrome, Mo¨bius syndrome, and congenital insensitivity
to pain. Typically, the congenital corneal anesthesia occurs
bilaterally; one-sided cases, however, are also described. The
cornea may be affected in isolation or as part of a sensory
deficit of the 1st and 2nd (and possibly 3rd) branch of the
trigeminal nerve [5, 6].
3. Congenital Causes of the Disease
Only scattered NK cases have been reported, highlighting the
rarity of NK development in congenital syndromes that are
rare per se. Those include the following congenital diseases,
all considered rare diseases.
Table 1: Aetiopathogenesis of neurotrophic keratitis.
Infections
Herpes simplex
Herpes zoster
Leprosy [16]
Corneal pathologies
Dystrophies
(i) Lattice
(ii) Granular
Iatrogenic injury
Contact lens wear
Surgeries
Laser-assisted in situ keratomileusis [17]
Corneal incision [18]
Lamellar and penetrating keratoplasty
Topical medications
Anaesthetics
Timolol
Betaxolol
Trifluridine
Sulfacetamide
Diclofenac sodium [19]
Toxic substances
Chemical burns
Exposure to oleoresin capsicum pepper
spray [20]
Exposure to hydrogen sulfide (H2S) [21]
Cranial nerve V palsy
Trigeminal neuralgia surgery
Neoplasm
Aneurysm
Facial trauma [10]
Congenital:
(i) Riley-Day syndrome
(ii) Mo¨bius corneal hypoesthesia
(iii) Goldenhar syndrome
(iv) Familial corneal hypesthesia
(v) (Familial trigeminal anesthesia)
(vi) Congenital insensitivity to pain with
anhidrosis
Systemic diseases
Diabetes
Vitamin A deficiency
Multiple sclerosis
Miscellaneous Increasing ageAdie’s syndrome [22]
3.1. Familial Dysautonomia (Riley-Day Syndrome). The
Riley-Day syndrome belongs to the hereditary sensory and
autonomic neuropathies (HSAN) and according to the
numerical classification of four distinct forms of HSAN
that was proposed by Axelrod and Gold-von Simson it is
also known as HSAN III [28]. It is an inherited autosomal
recessive disorder that affects the development and function
of nerves throughout the body, with a prevalence of less
than 1 on 1,000,000. This condition is almost exclusive to
individuals of Eastern European Jewish ancestry (Ashkenazi
Jews), and the incidence is 1 in 3,600 live births [28].
The carrier frequency in this population is about 1/30. If
both parents are carriers, there is a 25% chance with each
pregnancy to give birth to an affected child. Worldwide,
there have been approximately 600 diagnoses recorded since
the discovery of the disease, with approximately 350 of the
affected individuals still living [29].
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Corneal ulcerations have been reported in up to 50% of
patients [30]. However, it must be noted that this disease is
characterized by congenital alacrima, resulting in severe dry
eye rather than NK, and it has never been reported that the
corneal lesions in affected patients areNKulcers: there is only
one Riley-Day syndrome patient reported in the scientific
literature with a corneal epithelial defect caused by “loss of
corneal sensation and hypolacrimation” [31]. Therefore, it
cannot be determined whether this lesion was a NK PED or
a dry eye epithelial damage. Even if we assume that this was a
case of NK, the impact of Riley-Day syndrome on the overall
NK prevalence can safely be considered negligible.
3.2. Goldenhar-Gorlin Syndrome (Oculo-Auriculo-Vertebral
Spectrum). This syndrome was first described by Canton
in 1861 and Von Arlt in 1881, but only in 1952 Goldenhar-
Gorlin provided a comprehensive description. It is a rare
congenital defect (prevalence 1–9 in 100,000) whichmanifests
with a number of craniofacial abnormalities that affect the
structures embryologically derived from the first and second
branchial arches and usually involve the face (hemifacial
microsomia) and ears (microtia). In 50% of cases other
anomalies to heart and eyes (epibulbar dermoid) can be
found. Most cases are sporadic with 1-2% cases transmitted
as autosomal dominant (in this case the most likely affected
region is 14q32 and the male to female ratio is 2 : 1). It affects
between 1/5000 and 1/25000 live births [32]. Overall, the
ophthalmic anomalies involve approximately 66% of cases,
with epibulbar dermoids (28–35%), blepharoptosis (10%),
superior palpebral coloboma (20%), and microphthalmia
(18%). Corneal manifestations are thought to be related to
both decreased tear production and neuroparalytic keratitis,
possibly due to aplasia or hypoplasia of the trigeminal nuclei,
as can be retrieved from case reports involving a few children
or young adults [33–35]. In addition, an isolated involvement
of the facial nerve can be observed in approximately 20% of
cases.
The series published by Mansour et al. [36] does not
mention NK as one of the ocular manifestations of this
syndrome in 57 consecutive patients. In fact, only one case
of corneal anesthesia associated with epithelial punctate
keratopathy with this disease has ever been reported [37].
The typical asymmetric facial presentation of this syndrome
suggests that this could be a case of exposure keratopathy;
however, even if we assume that this was a case of NK, the
impact of Goldenhar-Gorlin syndrome on the overall NK
prevalence can safely be considered negligible.
3.3. Mo¨bius Syndrome. This extremely rare disease was first
described by the ophthalmologist P.J. Mo¨bius in 1888, who
described a few patients with the concomitant presence
of a nonprogressive congenital paralysis of the facial and
abducens nerves.The actual prevalence is unknown; however,
only approximately 300 cases have been reported in the
literature to date with no differences in gender [38]. Most
cases of Mo¨bius syndrome are isolated sporadic cases with
no notable family history. It is estimated that there are, on
average, 2 to 20 cases per million births. In a study conducted
on theDutch population in 1996, an incidence of 1/189000 live
births was found [39]. It must be noted that in this syndrome
it is not the trigeminal nerve, but the facial nerve, that is
involved. Specifically, the Mo¨bius syndrome is caused by an
abnormal development of the 7th cranial nerve (facial) in all
patients and of the 6th cranial nerve (abducens) in 75% of
the cases. Only in a minority of cases other cranial nerves,
including the trigeminal nerve, can be involved. Therefore,
it is more likely that a corneal lesion, in the context of
this syndrome, is caused by exposure keratopathy (by facial
paresis) and not by NK. While it is theoretically possible
that a subset of patients affected by Mo¨bius syndrome with
trigeminal involvement have corneal hypesthesia, NK cases
have not yet been described and, therefore, there is no impact
of this syndrome on the overall NK prevalence. On the other
hand, other ophthalmic anomalies have been described in
this syndrome, including congenital ptosis, epicanthus, and
hypertelorism.
3.4. Familial Corneal Hypesthesia (Familial Trigeminal Anes-
thesia). The prevalence of this condition is unknown, and
only scattered case reports have been published in scien-
tific literature. However, these reports do not differentiate
between isolated trigeminal anesthesia and corneal hypes-
thesia associated with the other syndromes listed above [40].
Therefore, the impact of familial trigeminal anesthesia on the
overall NK prevalence can safely be considered negligible.
3.5. Congenital Insensitivity to Pain with Anhidrosis (CIPA).
The exact prevalence of this rare condition is unknown.
According to scientific literature only 52 cases of CIPA have
ever been reported worldwide, of which only 14 had corneal
involvement [41]. Considering the extreme rarity of this
condition, even if we assume that the cornea was involved in
all cases during the patients’ life, the impact of CIPA on the
overall NK prevalence can safely be considered negligible.
However, the early diagnosis andprompt treatment of this
rare condition are mandatory to prevent corneal complica-
tions such as scarring and perforation.
Regardless of the cause behind the damage to corneal
sensory innervation, once NK develops, the corneal epithe-
lium is the first target of the disease, which begins with
dystrophic changes of the epithelial cells and, later, with frank
epithelial defects that have a poor tendency to spontaneous
healing. Epithelial damage of increasing severity is observed
according to the stage of the disease. Progression of the
disease can lead to corneal ulceration, infection, melting,
perforation, and, ultimately, loss of sight [6].
4. Clinical Staging of the Disease
According to theMackie classification, it is possible to classify
neurotrophic keratitis into three stages (1 to 3 in order of
increasing severity) [6].
(i) Stage 1 is characterized by punctate keratopathy
and/or corneal epithelial hyperplasia and irregularity,
whichmay be associatedwith superficial neovascular-
ization and stromal scarring. In addition dry eye signs
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may be observed, including vital dye (such as rose
bengal) staining of the inferior palpebral conjunctiva
and decreased tear film break-up time.
(ii) Stage 2 is characterized by a persistent corneal
epithelial defect (PED), typically oval or circular in
shape, with smooth and rolled edges. An area of
poorly adherent opaque and oedematous epithelium
is typically found rolled-up around the margin of
the epithelial defect. As this loose epithelium can
easily detach spontaneously, a rapid enlargement of
the defect is often observed. Oedema of the corneal
stroma may also be present, and it is not uncommon
to observe also an inflammatory reaction in the
anterior chamber.
(iii) Stage 3 often ensues if stages 1 and 2 are not treated
appropriately. In this stage the corneal stroma is
involved and a corneal ulcer is observed. Corneal
ulceration tends to progress to perforation and/or
stromal melting if not promptly and properly treated.
Corneal melting and perforation can be also iatro-
genically caused by inappropriate use of topical
steroids or by secondary infections of the nonhealing
ulcer.
5. Clinical Diagnosis of the Disease
The medical history and clinical findings are crucial for
making a proper diagnosis. Anamnesis often highlights sys-
temic diseases, previous neural surgeries, recurrent corneal
herpetic infections, trauma, and topical drug abuse. Other
characteristic observations include a disproportion between
clinical signs as observed at the slit lamp and symptoms
as referred by the patient, who is often completely asymp-
tomatic. In fact, corneal sensitivity is a key information to
orientate the diagnosis. Obviously, considering all this, it is
clear thatmaking a diagnosis of congenital corneal anesthesia
andNK is extremely challenging in young children, unless the
diagnosis of a well-known syndrome causing corneal anes-
thesia is confirmed. In fact, in adult, collaborative patients, a
qualitative assessment of corneal sensitivity reduction can be
easily measured using a piece of twisted cotton, but a quan-
titative evaluation using a Cochet-Bonnet or no-contact gas
esthesiometer is preferred and should bemandatory. Cochet-
Bonnet esthesiometry is the most widely used method and it
is performed by touching the central and peripheral cornea
with a nylon thread that can be elongated up to 60mm
(the longer the thread, the lighter the touch on the cornea)
and by recording the patient’s response. All the different
quadrants of the cornea have to be tested separately because
in some cases, including herpes simplex and zoster keratitis,
the impaired corneal sensitivity may be only sectorial [6].
This test is difficult to perform, if possible at all, in young
children, who are not collaborative and are not able to tell to
the ophthalmologist at which length of the Cochet-Bonnet
thread they feel the corneal sensation upon touching. The
use of in vivo corneal confocal microscopy to visualize the
altered subepithelial nerve plexus is also not feasible in young
children.
Slit lamp examination can be of great help, especially
in children, to evidence the characteristics corneal lesions
according to disease severity. Iris atrophy may be a sign of
previous herpes infection or previous intraocular inflamma-
tion, which sometimes is observed in stage 2 NK patients
[42]. There may be optic nerve pallor or swelling due to
an intracranial tumor that causes trigeminal compression
and impairment; therefore, a complete visit including dilated
fundus oculi examination must always be carried out; in
the case of visualization of optic nerve head changes it
is always important to exclude glaucoma by intraocular
pressure testing and visual field examination [43, 44].
Additionally, a clinical evaluation of the different cranial
nerves’ function can help localize the cause of the decreased
corneal sensation. For instance, an isolated dysfunction ofVII
and VIII cranial nerves may indicate an acoustic neuroma or
damage from surgical resection of the lesion, while the paresis
of cranial nerves III, IV, and VI may indicate an aneurysm or
cavernous sinus pathology that can also affect the trigeminal
nerve.
Lastly, the eyelids also need to be carefully examined for
both diagnostic and prognostic reasons. In fact, eyelids that
do not close properly not only indicate a cranial nerve VII
palsy and help in the disease diagnosis but also can worsen
the clinical picture and accelerate progression towards stage
3 disease for epithelial exposure by lagophthalmos [6].
Corneal anaesthesia is the hallmark of NK and, therefore,
the presence of ocular symptoms such as burning, foreign
body sensation, photophobia, and dry eye easily orientates
the diagnosis towards other ocular surface diseases. Infective,
toxic, or immune corneal ulcers also differ from NK as
they are typically accompanied by ocular inflammation and
stromal infiltrates. To exclude the presence of an infective
ulcer, a microbiologic examination needs to be performed
(in the presence of a nonhealing corneal lesion, not only
if infiltrates are present, microbiologic exams should always
be performed). In order to exclude toxic corneal ulcers, all
topical treatments must be discontinued. In order to exclude
immune corneal ulcers, a thorough systemic evaluation for
immune disorders should also be carried out.
Since superficial corneal vascularisation and epithelial
defects can also be seen in limbal stem cell deficiency an
additional examination that can be performed in doubtful
cases is impression cytology, a minimally invasive technique
that allows the direct visualization and identification of the
corneal or conjunctival epithelial phenotype by Periodic Acid
Schiff staining or immunostaining for cytokeratins [6].
6. Prognosis of the Disease
The prognosis of neurotrophic keratitis depends upon a
wide range of factors, including the specific cause behind
corneal sensitivity impairment, the degree of corneal hypo/
anesthesia, and the association with other ocular surface
diseases such as dry eye, exposure keratitis, and limbal stem
cell deficiency. The prognosis of congenital NK is usually
poor as no medically effective therapy is currently available
and due to the chronic and degenerative nature of the
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disease most patients are likely to end up developing disease
complications or associated ocular surface alterations.
While the presence of associated ocular surface diseases
may differently affect the prognosis, it is well known that
usually the more severe is the corneal sensory impairment,
the higher is the rapidity of disease progression towards
corneal melting, perforation, and sight loss due to anatomical
loss of the eye or permanent loss of corneal transparency [6].
Nevertheless, even in patients that do not have a complete
corneal anesthesia or associated diseases such as secondary
bacterial infection, and sometimes even despite early and
appropriate therapy, neurotrophic keratitis may still progress
to stage 3 (corneal ulcer) disease. When a neurotrophic
corneal ulcer develops, it always requires prompt action
in order to stop the stromal lysis and prevent perforation.
Unfortunately, even when corneal perforation is avoided,
once a corneal ulcer develops a permanent decrease in visual
acuity from corneal scarring and astigmatism can still be the
final outcome of the disease [6].
7. Prevention
Given the wide range of underlying pathologies observed
in NK, no consistent approach to prevention is realistic.
The most important preventive approach is the prompt
identification of stage 1 patients who can be addressed with
intense and continuous ocular lubrication with preservative
free compounds. The prevention of disease progression with
the use of therapeutic contact lenses is also a valid approach
for small persistent epithelial defects.
8. Treatment
NK treatment largely depends on disease stage and severity.
In fact, the therapeutic approach for stage 1 disease is mostly
aimed at preventing epithelial breakdown, while treatment
for stages 2 and 3 is mostly aimed at facilitating healing of the
corneal lesion in order to prevent irreparable consequences
on visual function. More specifically, in the presence of
a persistent epithelial defect, treatment aims at preventing
stromal involvement with corneal ulcer formation, while
more advanced cases, with the presence of a corneal ulcer
and stromal melting, require immediate attention to stop the
stromal lysis and prevent corneal perforation. This is often
obtained by surgery.
Although pharmacological treatments for NK are being
intensively studied, with currently ongoing phase 2 clinical
trials evaluating growth factors and neuropeptides in both
Europe and USA [31, 45], none are yet available. However,
the use of preservative-free artificial tears may help improve
the corneal surface at all stages of disease, and continuous
lubrication with preservative-free compounds needs to be
recommended, especially in children, not only to stage 1
patients. The use of preservative free topical antibiotic eye
drops is often encouraged and recommended in children to
prevent superinfections in eyes with NK at stages 2 and 3;
however, itmust also be kept inmind thatNK lesions are non-
infective and, therefore, the use of topical antibiotics is only
preventive. When ocular inflammation is present, especially
in the case of hypopyon visualization in the anterior chamber,
topical steroids have been proposed for NK and may be
highly necessary; however, their use is very controversial and
must be extremely cautious since steroids may increase the
risk of corneal melting and perforation by inhibiting stromal
healing. Topical nonsteroidal anti-inflammatory drugs may
also inhibit the healing process and should be avoided since
their added benefit to control anterior chamber inflammation
would be minimal. Regardless of the concomitant use of
topical steroids, in the event of stromal melting, the use of
topical collagenase inhibitors such as N-acetylcysteine [46]
and systemic administration of tetracycline or medroxypro-
gesterone has been suggested and is usually considered a valid
therapeutic option [47]. Nonpharmacological treatments for
NK include therapeutic corneal or scleral contact lenses in
the event of PED to promote corneal epithelial healing and
postpone severe corneal complications [48]. Prolonged ther-
apeutic contact lens use may increase the risk of secondary
infections and the concomitant use of topical antibiotics is
mandatory [49].
Surgical treatments should be avoided, especially in
children, as they are all burdened by a reduction in visual
function. Therefore, surgery is usually reserved for refrac-
tory cases or for cases that show rapid disease progression
towards stromal thinning despite all the best therapeutic
efforts. Partial or total tarsorrhaphy is the most simple and
widespread procedure used to promote corneal healing in the
presence of a neurotrophic PED. Surgical tarsorrhaphy may
be performed easily and the tarsorrhaphy opening may be
enlarged a few weeks after corneal healing; however, opening
a tarsorrhaphy prematurely often results in an early disease
recurrence. Alternatively to the tarsorrhaphy, the use of
botulinum A toxin injection of the eyelid elevator muscle has
been proposed to cover the PED and promote healing [50].
Amniotic membrane transplantation (AMT) is a surgical
technique for ocular surface reconstruction that carries rela-
tively good results and can be considered in the management
of refractory neurotrophic corneal ulcers. AMT is relatively
easy to perform and is effective in promoting corneal epithe-
lial healing, reducing vascularisation, and reducing ocular
surface inflammation. A multilayer AMT has also been
proposed for treating deeper neurotrophic corneal ulcers [51].
The conjunctival flap is a more invasive procedure that
should be restricted only to very severe cases with impending
perforations. In fact, although this surgical procedure is
very effective as it is able to restore ocular surface integrity
and provide metabolic and mechanical support for corneal
healing, it also severely compromises visual function and the
esthetic outcome is also very poor: in this procedure, the deep
corneal ulcer (or corneal perforation) is covered by a pedun-
culated conjunctival flap secured in place by fine sutures that
provides vascular support to the nonhealing cosmetic cornea.
Themain goal of this procedure is to preserve the anatomical
integrity of the eye, but it does obviously severely impact
visual function since the flap vascularizes [52, 53].
In the presence of a small perforation (less than 3mm)
a less invasive approach can be used, by the application of
cyanoacrylate glue on the lesion, followed by the application
of a soft bandage contact lens or AMT. Larger defects require
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a conjunctival flap or lamellar keratoplasty; however, it must
be kept in mind that the success rate of corneal transplants
in NK patients is very low due to the lack of trophic support,
with consequent poor wound healing and risk of PED/ulcer
recurrence [54].
In children with congenital corneal anesthesia or other
forms of disease that may cause NK, a prompt diagnosis and
a life-long monitoring and therapy are important to prevent
amblyopia and permanent visual damage. The main goal of
therapy is to prevent the formation of epithelial defects. An
intensive lubrication is essential.Thewearing of safety glasses
to avoid self-inflicted injuries is also generally recommended
in young children.
If persistent epithelial defects or frank corneal ulcers
develop, a fast and aggressive therapy is necessary in order
to avoid a corneal perforation. In persistent epithelial defects,
soft highly hydrophilic contact lenses can be used together
with prophylactic application of antibiotic unpreserved eye
drops.
When ulcers develop, amniotic membrane transplanta-
tion may be considered in children. Tarsorrhaphy and a
protective ptosis by Botulinum toxin injection in the levator
palpebrae can be considered inmore severe cases [55, 56], but
the amblyogenic potential of all these treatments must always
be considered in young children.
9. Conclusions
The diagnosis of congenital corneal anesthesia is a real
challenge for ophthalmologists because the typical diagnostic
tests, such as Cochet-Bonnet corneal esthesiometry, are often
not feasible in young children. Therefore, it is mandatory for
the ophthalmologists to be aware of the rare systemic dis-
orders that can cause congenital corneal anesthesia and NK,
including the Riley-Day, Mo¨bius, and Goldenhar syndromes.
Once corneal anesthesia is suspected or a corneal lesion is
observed in the affected children, the clinical management is
also a real challenge. In fact, although a number of promising
clinical trials are ongoing to test therapeutic interventions
for NK, there is currently no medication available to restore
corneal sensitivity and cure the disease. All current medical
treatments, from intense ocular lubrication to therapeutic
contact lens and to autologous serum eye drops, are useful
to prevent or slow down progression in patients diagnosed
with stage 1 or early stage 2 disease. However, once a large
epithelial defect or a frank neurotrophic corneal ulcer is
present, surgery is often needed to prevent further disease
progression and avoid corneal perforation. Unfortunately,
surgical interventions such as tarsorrhaphy, amniotic mem-
brane transplantation, or conjunctival flap inevitably cause
a decrease in visual function, which can result in amblyopia
when performed in young children.
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